Husted T L, Neff G, Thomas M J, Gross T G, Woodle E S, Buell J F
The Israel Penn International Transplant Tumor Registry, University of Cincinnati, Cincinnati, Ohio.
Am J Transplant. 2006 Feb;6(2):392-7. doi: 10.1111/j.1600-6143.2005.01179.x.
Sarcoma is generally a rare disease in the US, with poor survival in patients with both primary angiosarcoma and metastatic disease from sarcoma and GIST. In order to determine if liver transplantation for sarcoma is a realistic option, we examined records of all patients in the US component of the Israel Penn International Transplant Tumor Registry were reviewed. Those patients with liver failure from primary or metastatic liver sarcoma were evaluated. Patient outcome analysis was then performed. Patient and tumor demographics were reviewed as well as patient survival after transplantation. 19 patients are identified having received liver transplantation after treatment for sarcoma of the liver, 6 patients with primary hepatic sarcoma and 13 patients with metastatic sarcoma of the liver. Recurrence was almost universal in 18 of 19 patients (95%) after a median interval of 6 months. Survival for the group as a whole was 47% for 1-year, 15% for 3-years and 5% for 5-years. Given the early recurrence of tumor and meager 1-year survival outcome, liver transplantation is a poor therapeutic choice for patients with either primary or metastatic liver sarcoma, including high-grade leiomyosarcoma (GIST) regardless of primary site or primary therapy.
在美国，肉瘤通常是一种罕见疾病，原发性血管肉瘤以及肉瘤和胃肠道间质瘤（GIST）转移性疾病患者的生存率较低。为了确定肉瘤肝移植是否是一种现实的选择，我们查阅了以色列宾夕法尼亚国际移植肿瘤登记处美国部分所有患者的记录。对那些因原发性或转移性肝肉瘤导致肝衰竭的患者进行了评估。然后进行了患者预后分析。回顾了患者和肿瘤的人口统计学数据以及移植后的患者生存率。确定有19例患者在接受肝脏肉瘤治疗后接受了肝移植，其中6例为原发性肝肉瘤患者，13例为肝转移性肉瘤患者。19例患者中有18例（95%）在中位间隔6个月后几乎普遍复发。该组患者的1年生存率为47%，3年生存率为15%，5年生存率为5%。鉴于肿瘤早期复发且1年生存结果不佳，肝移植对于原发性或转移性肝肉瘤患者，包括高级别平滑肌肉瘤（GIST）患者，无论原发部位或初始治疗如何，都是一种较差的治疗选择。
